Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders (Q38240733)

31 August 2017

title

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders (English)

1 reference

31 August 2017

Ricky W Johnstone

2

0 references

author name string

Katrina J Falkenberg

series ordinal

1

1 reference

31 August 2017

publication date

18 August 2014

1 reference

Nature Reviews Drug Discovery

31 August 2017

published in

1 reference

31 August 2017

volume

13

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

673-691

1 reference

Genetic syndromes caused by mutations in epigenetic genes

31 August 2017

cites work

1 reference

A decade of exploring the cancer epigenome - biological and translational implications

21 January 2018

1 reference

The complex language of chromatin regulation during transcription

21 January 2018

1 reference

Chromatin modifications and their function

21 January 2018

1 reference

Cancer epigenetics: from mechanism to therapy

21 January 2018

1 reference

Targeting epigenetic readers in cancer.

21 January 2018

1 reference

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

21 January 2018

1 reference

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension

21 January 2018

1 reference

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

21 January 2018

1 reference

Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors

21 January 2018

1 reference

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

Effects of a novel arginine methyltransferase inhibitor on T-helper cell cytokine production

21 January 2018

1 reference

Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors

21 January 2018

1 reference

New and emerging HDAC inhibitors for cancer treatment

21 January 2018

1 reference

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

21 January 2018

1 reference

Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor

21 January 2018

1 reference

Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction

21 January 2018

1 reference

Tranylcypromine: new perspectives on an "old" drug

21 January 2018

1 reference

Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials

21 January 2018

1 reference

Selective inhibition of BET bromodomains

21 January 2018

1 reference

Suppression of inflammation by a synthetic histone mimic

21 January 2018

1 reference

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

Targeting MYC dependence in cancer by inhibiting BET bromodomains

21 January 2018

1 reference

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

21 January 2018

1 reference

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

21 January 2018

1 reference

Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors

21 January 2018

1 reference

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals

21 January 2018

1 reference

Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation.

21 January 2018

1 reference

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

21 January 2018

1 reference

Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors

21 January 2018

1 reference

Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells

21 January 2018

1 reference

n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells

21 January 2018

1 reference

AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

21 January 2018

1 reference

The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity

21 January 2018

1 reference

The 8;21 translocation in leukemogenesis

21 January 2018

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor

21 January 2018

1 reference

Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins

21 January 2018

1 reference

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer

21 January 2018

1 reference

Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice.

21 January 2018

1 reference

Hdac3 is essential for the maintenance of chromatin structure and genome stability

21 January 2018

1 reference

Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice

21 January 2018

1 reference

Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function

21 January 2018

1 reference

A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.

21 January 2018

1 reference

HDAC2 negatively regulates memory formation and synaptic plasticity.

21 January 2018

1 reference

An epigenetic blockade of cognitive functions in the neurodegenerating brain

21 January 2018

1 reference

Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development

21 January 2018

1 reference

Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function

21 January 2018

1 reference

Class IIA HDACs in the regulation of neurodegeneration

21 January 2018

1 reference

HDAC4 inhibits cell-cycle progression and protects neurons from cell death

21 January 2018

1 reference

An essential role for histone deacetylase 4 in synaptic plasticity and memory formation

21 January 2018

1 reference

Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems

21 January 2018

1 reference

Loss of deacetylation activity of Hdac6 affects emotional behavior in mice

21 January 2018

1 reference

Neurodegenerative tauopathies

21 January 2018

1 reference

Acetylation of tau inhibits its degradation and contributes to tauopathy

21 January 2018

1 reference

The acetylation of tau inhibits its function and promotes pathological tau aggregation

21 January 2018

1 reference

Acetylated tau neuropathology in sporadic and hereditary tauopathies

21 January 2018

1 reference

Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition.

21 January 2018

1 reference

Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance

21 January 2018

1 reference

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?

21 January 2018

1 reference

Acetylation targets mutant huntingtin to autophagosomes for degradation

21 January 2018

1 reference

Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease

21 January 2018

1 reference

Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation

21 January 2018

1 reference

Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS

21 January 2018

1 reference

Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease

21 January 2018

1 reference

Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease

21 January 2018

1 reference

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

21 January 2018

1 reference

Histone deacetylases as regulators of inflammation and immunity

21 January 2018

1 reference

HDAC inhibitor therapy in autoimmunity and transplantation.

21 January 2018

1 reference

HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.

21 January 2018

1 reference

STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta

21 January 2018

1 reference

A phosphorylation-acetylation switch regulates STAT1 signaling

21 January 2018

1 reference

Requirement of histone deacetylase activity for signaling by STAT1.

21 January 2018

1 reference

Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity.

21 January 2018

1 reference

Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.

21 January 2018

1 reference

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

21 January 2018

1 reference

Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages

21 January 2018

1 reference

HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages.

21 January 2018

1 reference

Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes

21 January 2018

1 reference

Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.

21 January 2018

1 reference

Deacetylase inhibition promotes the generation and function of regulatory T cells.

21 January 2018

1 reference

Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells

21 January 2018

1 reference

HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization

21 January 2018

1 reference

Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity

21 January 2018

1 reference

Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression

21 January 2018

1 reference

Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production

21 January 2018

1 reference

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

21 January 2018

1 reference

Histone deacetylase inhibitors and HIV latency

21 January 2018

1 reference

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

21 January 2018

1 reference

The role of the CoREST/REST repressor complex in herpes simplex virus 1 productive infection and in latency

21 January 2018

1 reference

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

21 January 2018

1 reference

Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4

21 January 2018

1 reference

Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling.

21 January 2018

1 reference

Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases

21 January 2018

1 reference

Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

21 January 2018

1 reference

HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model

21 January 2018

1 reference

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

21 January 2018

1 reference

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia

21 January 2018

1 reference

Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma

21 January 2018

1 reference

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.

21 January 2018

1 reference

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer

21 January 2018

1 reference

Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities

21 January 2018

1 reference

A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests

21 January 2018

1 reference

Multi-targeted histone deacetylase inhibitors in cancer therapy.

21 January 2018

1 reference

Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling

21 January 2018

1 reference

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity

21 January 2018

1 reference

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion

21 January 2018

1 reference

Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs.

21 January 2018

1 reference

A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies

21 January 2018

1 reference

Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors

21 January 2018

1 reference

Dual-acting histone deacetylase-topoisomerase I inhibitors.

21 January 2018

1 reference

Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay

21 January 2018

1 reference

Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.

21 January 2018

1 reference

Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment

21 January 2018

1 reference

Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist

21 January 2018

1 reference

Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids

21 January 2018

1 reference

Development of a chimeric c-Src kinase and HDAC inhibitor

21 January 2018

1 reference

A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy

21 January 2018

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

21 January 2018

1 reference

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor

21 January 2018

1 reference

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

21 January 2018

1 reference

Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia

21 January 2018

1 reference

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

21 January 2018

1 reference

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

21 January 2018

1 reference

Immunogenic cell death in cancer therapy

21 January 2018

1 reference

Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.

21 January 2018

1 reference

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

21 January 2018

1 reference

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Differentiation of NUT midline carcinoma by epigenomic reprogramming

21 January 2018

1 reference

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

21 January 2018

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

21 January 2018

1 reference

HDAC inhibitor-based therapies: can we interpret the code?

21 January 2018

1 reference

Trials with 'epigenetic' drugs: an update

21 January 2018

1 reference

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials

21 January 2018

1 reference

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

Rational combinations using HDAC inhibitors

21 January 2018

1 reference

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

21 January 2018

1 reference

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

21 January 2018

1 reference

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

21 January 2018

1 reference

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

21 January 2018

1 reference

Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo

21 January 2018

1 reference

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 January 2018

1 reference

Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies

21 January 2018

1 reference

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies

21 January 2018

1 reference

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents

21 January 2018

1 reference

The TRAIL apoptotic pathway in cancer onset, progression and therapy

21 January 2018

1 reference

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

21 January 2018

1 reference

Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat

21 January 2018

1 reference

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

21 January 2018

1 reference

Multiple roles of HDAC inhibition in neurodegenerative conditions.

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

21 January 2018

1 reference

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

21 January 2018

1 reference

Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity

21 January 2018

1 reference

Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies

21 January 2018

1 reference

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

21 January 2018

1 reference

Clinical Toxicities of Histone Deacetylase Inhibitors

21 January 2018

1 reference

Spinal muscular atrophy: an update on therapeutic progress

21 January 2018

1 reference

Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines

21 January 2018

1 reference

Differential regulation of the SMN2 gene by individual HDAC proteins

21 January 2018

1 reference

Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice

21 January 2018

1 reference

Histone/protein deacetylases and T-cell immune responses

21 January 2018

1 reference

Histone deacetylase inhibitors in inflammatory disease.

21 January 2018

1 reference

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

21 January 2018

1 reference

Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis

21 January 2018

1 reference

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

21 January 2018

1 reference

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

21 January 2018

1 reference

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

21 January 2018

1 reference

Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.

21 January 2018

1 reference

Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells

21 January 2018

1 reference

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

21 January 2018

1 reference

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

21 January 2018

1 reference

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma

21 January 2018

1 reference

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti

21 January 2018

1 reference

Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly

21 January 2018

1 reference

Rad23 promotes the targeting of proteolytic substrates to the proteasome

21 January 2018

1 reference

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors

21 January 2018

1 reference

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

21 January 2018

1 reference

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

21 January 2018

1 reference

21 January 2018

ETO interacting proteins

1 reference

Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.

21 January 2018

1 reference

PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential

21 January 2018

1 reference

CBFbeta is critical for AML1-ETO and TEL-AML1 activity

21 January 2018

1 reference

The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.

21 January 2018

1 reference

Role of the polycomb repressive complex 2 in acute promyelocytic leukemia

21 January 2018

1 reference

Towards isozyme-selective HDAC inhibitors for interrogating disease.

21 January 2018

1 reference

Activity-based probes for proteomic profiling of histone deacetylase complexes

21 January 2018

1 reference

Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors

21 January 2018

1 reference

HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner

21 January 2018

1 reference

Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability

21 January 2018

1 reference

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

21 January 2018

1 reference

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

21 January 2018

1 reference

Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects

21 January 2018

1 reference

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth

21 January 2018

1 reference

Development of a histone deacetylase 6 inhibitor and its biological effects

21 January 2018

1 reference

Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

21 January 2018

1 reference

Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries

21 January 2018

1 reference

Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.

21 January 2018

1 reference

Discovery of the first histone deacetylase 6/8 dual inhibitors.

21 January 2018

1 reference

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

HDAC inhibitors: roles of DNA damage and repair

21 January 2018

1 reference

Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor

21 January 2018

1 reference

Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells

21 January 2018

1 reference

Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage

21 January 2018

1 reference

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

21 January 2018

1 reference

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

21 January 2018

1 reference

Histone deacetylase inhibitors disrupt the mitotic spindle assembly checkpoint by targeting histone and nonhistone proteins

21 January 2018

1 reference

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock

21 January 2018

1 reference

The role of histone acetylation versus DNA damage in drug-induced senescence and apoptosis

21 January 2018

1 reference

HDACs and the senescent phenotype of WI-38 cells

21 January 2018

1 reference

Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells

21 January 2018

1 reference

Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression

21 January 2018

1 reference

Revisiting the differentiation paradigm in acute promyelocytic leukemia

21 January 2018

1 reference

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.

21 January 2018

1 reference

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

21 January 2018

1 reference

Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells

21 January 2018

1 reference

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

21 January 2018

1 reference

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma

21 January 2018

1 reference

Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death

21 January 2018

1 reference

Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance

21 January 2018

1 reference

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

21 January 2018

1 reference

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

21 January 2018

1 reference

Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma

21 January 2018

1 reference

Cutting edge: chromatin remodeling as a molecular basis for the enhanced functionality of memory CD8 T cells

21 January 2018

1 reference

Histone acetylation is associated with differential gene expression in the rapid and robust memory CD8(+) T-cell response

21 January 2018

1 reference

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

21 January 2018

1 reference

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy

21 January 2018

1 reference

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

21 January 2018

1 reference

Histone deacetylases and the immunological network: implications in cancer and inflammation

21 January 2018

1 reference

Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs.

21 January 2018

1 reference

Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions

21 January 2018

1 reference

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

21 January 2018

1 reference

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

21 January 2018

1 reference

Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis

21 January 2018

1 reference

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

Targeting tumor angiogenesis with histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway

21 January 2018

1 reference

Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection

21 January 2018

1 reference

Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.

21 January 2018

1 reference

Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication

21 January 2018

1 reference

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

21 January 2018

1 reference

Vascular histone deacetylation by pharmacological HDAC inhibition

31 March 2020

1 reference

FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70

31 March 2020

1 reference

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma

31 March 2020

1 reference

Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice

31 March 2020

1 reference

The role of HDAC6 in Alzheimer's disease

31 March 2020

1 reference

The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma

31 March 2020

1 reference

Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia

31 March 2020

1 reference

Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.

31 March 2020

1 reference

12 December 2020

Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17).

1 reference

12 December 2020

The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

1 reference

12 December 2020

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice

1 reference

12 December 2020

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

1 reference

12 December 2020

P-glycoprotein substrates and antagonists cluster into two distinct groups

1 reference

12 December 2020

Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

1 reference

12 December 2020

Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B

1 reference

12 December 2020

Histone-deacetylase inhibitors for the treatment of cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4360

1 reference

31 August 2017

1 reference